

## 8<sup>th</sup> InterAmerican Oncology Conference

'Current Status and Future of Anti-Cancer Therapies'

October 17-18, 2019

Buenos Aires, Argentina

### FIRST ANNOUNCEMENT

The 8<sup>th</sup> Conference of IAOC "**Current Status and Future of Anti-Cancer Therapies**" will be held in Buenos Aires, Argentina in October 17<sup>th</sup> and 18<sup>th</sup>, 2019.

An outstanding faculty of speakers from the United States and Europe has committed in this meeting. The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21<sup>st</sup> century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.

This meeting is the primary opportunity for oncologists, hematologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care.

### CO- CHAIRS

**Alex Adjei**, Rochester, USA

**Román Pérez Soler**, New York, USA

**Antoni Ribas**, Los Angeles, USA

### ORGANIZING COMMITTEE

**Román Pérez Soler**, New York, USA

**Andrea Blanco**, Buenos Aires, Argentina

### SCIENTIFIC COMMITTEE

**Alex Adjei**, M.D., Ph.D., Mayo Clinic, Rochester, USA

**Kenneth C. Anderson**, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA

**Carlos L. Arteaga**, M.D., Harold C. Simmons Cancer Center, Texas, USA

**Roman Perez Soler**, M.D., Albert Einstein College of Medicine, New York, USA

**Antoni Ribas**, M.D., Ph.D., UCLA, Los Angeles, USA

**Josep Tabernero**, M.D., Ph.D., Vall d'Hebron University Hospital, Barcelona, Spain

**FACULTY (PROVISIONARY)****Alex A. Adjei, M.D., Ph.D.**

Consultant in Oncology  
Professor of Oncology  
Mayo Clinic  
Rochester, Minnesota, USA

**Kenneth C. Anderson, M.D.**

Kraft Family Professor of Medicine  
Harvard Medical School  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA

**Stephen M. Ansell, M.D., Ph.D.**

Professor of Medicine  
Chair Lymphoma Group  
Mayo Clinic  
Rochester, Minnesota, USA

**Carlos L. Arteaga, M.D.**

Professor of Medicine and Cancer Biology  
Professor of Medicine  
Director, UTSW Harold C. Simmons Cancer Center  
Associate Dean of Oncology  
Lisa K. Simmons Distinguished Chair in Comprehensive Oncology  
Dallas, Texas, USA

**Carlos H. Barrios, M.D.**

Centro de Pesquisa Clínica, Hospital São Lucas, PUCRS  
Latin American Cooperative Oncology Group (LACOG)  
Porto Alegre RS, Brazil

**Joaquim Bellmunt, M.D., Ph.D.**

Associate Professor, Medicine,  
Harvard Medical School  
Bladder Cancer Center  
Dana-Farber Cancer Institute  
Boston, Massachusetts, USA

**Jorge Cortés, M.D.**

Professor of Medicine  
Chief, CML & AML Sections  
Deputy Chair, Department of Leukemia  
M.D. Anderson Cancer Center  
Houston, Texas, USA

**Charles Drake, M.D., Ph.D.**

Director GenitoUrinary Oncology  
Co- Director Immunotherapy  
Associate Director for Clinical Research  
Herbert Irving Comprehensive Cancer Center  
Columbia University Medical Center  
NY, New York, USA

**Román Pérez-Soler, M.D.**

Chairman, Department of Oncology  
Montefiore Medical Center  
Professor of Medicine and Molecular Pharmacology  
Deputy Cancer Center Director  
Albert Einstein College of Medicine  
Bronx, , New York, USA

**Gabriel A. Rabinovich, Ph.D.**

Head of the Laboratoy of Immunopathology  
Instituto de Biología y Medicina Experimental (IBYME)  
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)  
Member of the USA National Academy of Sciences  
Buenos Aires, Argentina

**Antoni Ribas, M.D., Ph.D.**

Professor of Medicine and Surgery  
Professor of Molecular and Medical Pharmacology  
Director Tumor Immunology Program, Jonsson  
Comprehensive Cancer Center (JCCC)  
David Geffen School of Medicine, UCLA  
Chair, Melanoma Committee at SWOG  
Los Angeles, California, USA

**Josep Tabernero, M.D., Ph.D.,**

Chairman Medical Oncology Department  
Vall d'Hebron University Hospital  
Barcelona, Spain

## **PRELIMINARY PROGRAM**

### **NEW ANTICANCER THERAPIES**

- **Promising Novel Agents in Early Clinical Trials:**  
Alex A. Adjei, Rochester, USA
- **Novel Combination Approaches for Cancer Immunotherapy:**  
Charles Drake, NY, USA
- **Biomarkers for Cancer Immunotherapy:**  
Antoni Ribas, California, USA
- **Emerging Checkpoints in Immune and Vascular Signaling Programs in Cancer:**  
Gabriel Rabinovich, Buenos Aires, Argentina

### **MELANOMA**

- **New Treatments in Melanoma:**  
Antoni Ribas, California, USA

### **BREAST CANCER**

- **New Drugs and Treatments in Breast Cancer:**  
Carlos L. Arteaga, Texas, USA
- **Challenges in the Genomic Selection of Patients:**  
Carlos Barrios, Porto Alegre, Brazil

### **GU CANCER**

- **Novel Therapies in Prostate and Renal Cancer:**  
Charles Drake, NY, USA
- **The Evolution of Targeted Therapy and Checkpoint Inhibitors in Bladder Cancer:**  
Joaquim Bellmunt, Boston, USA

## **GI CANCER**

- **Novel Therapies in GI Cancer:**  
Josep Tabernero, Barcelona, Spain

## **LUNG CANCER**

- **What's new in the Management of SCLC and Mesothelioma:**  
Alex A. Adjei, Rochester, USA
- **Advances in the Treatment of Advanced NSCLC:**  
Román Pérez Soler, New York, USA

## **HEMATOLOGICAL MALIGNANCIES**

- **New Therapies and Treatments in Lymphoma:**  
Stephen Ansell, Rochester, USA
- **Multiple Myeloma:**  
Kenneth C. Anderson, Boston, USA
- **Novel Drug Development in Leukemia:**  
Jorge Cortés, Houston, USA

## **CONFERENCE SECRETARIAT AND INFORMATION**

E-mail: [secretariat@oncologyconferences.com.ar](mailto:secretariat@oncologyconferences.com.ar)

Web: [www.oncologyconferences.com.ar](http://www.oncologyconferences.com.ar)